Chugai's productive internal pipeline and relationship with Roche support a narrow moat.
We are raising our fair value estimate for Chugai to JPY 4,560 per share from JPY 4,010 following 2017 financial results, as we have slightly raised our estimates for Chugai's overseas revenue potential from ALK-positive lung cancer drug Alecensa, immunology drug Actemra, and recently approved hemophilia drug Hemlibra. In 2017, Actemra and Alecensa led growth, with Chugai's overall business seeing strong growth in revenue (8.6%) and core operating profits (28%). We still expect Chugai to see pos...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.